Hiki ke hoʻohana ʻia nā biologics e like me Canakinumab (monoclonal antibody), Anakinra (monoclonal antibody) a me Rilonacept (fusion protein ) ma ke ʻano he therapeutics e kāohi ana i ka mumū i nā poʻe maʻi COVID-19. Eia kekahi, hiki i nā antibodies monoclonal hoʻolālā ke hāʻawi i ka pale ʻole passive ma ka hoʻopau ʻana i ka maʻi SARS-CoV-2 e pale aku i ka maʻi.
Ke hoʻololi nei ʻo Drug Discovery i kona ala mai nā lāʻau lapaʻau mole liʻiliʻi i nā biologics nona nā protein a me nā antibodies monoclonal e like me nā therapeutics. ʻO kēia ma muli o ke kikoʻī kiʻekiʻe e alakaʻi ana i ka pono kiʻekiʻe o nā lāʻau lapaʻau i hoʻokumu ʻia i ka protein a me nā hopena ʻaoʻao haʻahaʻa i ka hoʻohālikelike ʻia me nā mole liʻiliʻi. ʻO nā therapeutics i hoʻokumu ʻia i ka antibody e kāohi ana i ka mumū kekahi o nā ʻohana lāʻau biologic nui loa ma nā ʻāpana biotech/pharmaceutical.
ʻO ka maʻi ahulau COVID-19 i hala koke nei e ʻoi aku ka pili o ka ʻike ʻana a me ke kuhikuhi ʻana i nā lāʻau lapaʻau e hoʻohana ana i ka hoʻohana hou ʻana i nā lāʻau lapaʻau e kū nei 1 e hakakā i ka maʻi COVID-19. ʻO kekahi o lākou ka hoʻohana ʻana i nā antibodies monoclonal i loaʻa i hiki ke hoʻohana ʻia e kūʻē i ka NLRP3 inflammasome, kahi pahuhopu lāʻau lapaʻau hou i hāpai ʻia ma kaʻu ʻatikala i ka lā 9 Mei 2020. Ua wehewehe kēia ʻatikala i ke koʻikoʻi o ka NLRP3 inflammasome ma ke ʻano he pahuhopu lāʻau lapaʻau hou no ka mālama ʻana iā COVID-19 2. Ma kēia ʻano, ʻo ka hoʻohana ʻana i nā antibodies monoclonal e kūʻē iā IL-1 (interleukin-1)-beta a me interleukin-18 (IL-18), ʻo ia nā hōʻailona hall o ka hoʻāla ʻana o ka inflammasome 3, hiki ke hōʻoia i ka maikaʻi e kūʻē iā COVID-19 ma ka hōʻemi ʻana i ka mumū a pēlā e kōkua ai i nā maʻi.
ʻO Canakinumab i loaʻa i kēia manawa, kahi antibody monoclonal kanaka i kuhikuhi ʻia i ka IL-1 beta i kūʻai ʻia ma lalo o ka inoa inoa ʻo Ilaris 4 , he lāʻau lapaʻau no ka mālama ʻana i ka ʻōʻō idiopathic juvenile systemic a me ka maʻi Still ikaika. Hiki ke hoʻāʻo ʻia a hoʻāʻo ʻia kēia i nā poʻe maʻi COVID-19 e hōʻemi i ka mumū a me ka holomua o ka maʻi. Eia kekahi, ʻo Anakinra, i kūʻai ʻia ʻo Kineret®, he antagonist receptor IL-1 recombinant (IL-1ra) hiki ke hoʻohana ʻia e ālai i ka receptor a pale i ka hana o IL-1 beta. ʻO kekahi biologic i loaʻa ʻo Rilonacept (Arcalyst ® ) 4, kahi protein fusion dimeric i haku ʻia me ka ligand-binding domain o ka receptor IL-1 kanaka a me ka protein accessory receptor IL-1 hiki ke hoʻāʻo ʻia e pale i ka hoʻāla ʻana o IL-1 beta.
Ma waho aʻe o ke kuhikuhi ʻana i nā hopena ma hope o COVID-19, e like me ka NLRP3 i ʻōlelo ʻia ma luna, ʻo ka hoʻomohala ʻana i nā antibodies monoclonal hoʻolālā e hiki ke hoʻopau i ka maʻi a hāʻawi i ka pale ʻana passive i ka heluna kanaka, he manaʻo hoihoi nō hoʻi a hiki i ka wā e hoʻomohala ʻia ai kahi lāʻau pale 5,6,7.
***
E hoʻomaopopo ':
- Soni, R., 2020. ʻO kahi ala hou e 'hoʻohana hou' i nā lāʻau lapaʻau e kū nei no COVID-19. ʻElepa ʻepekema. Paʻi ʻia ma Mei 7, 2020. Loaʻa ma ka pūnaewele ma http://scientificeuropean.co.uk/covid-19/a-novel-approach-to-repurpose-existing-drugs-for-covid-19/
- Soni, R., 2020. NLRP3 Inflammasome: He Pahu Lapaʻau Hou no ka mālama ʻana i nā maʻi maʻi COVID-19. ʻElepa ʻepekema. Paʻi ʻia ma Mei 09, 2020. Loaʻa ma ka pūnaewele ma http://scientificeuropean.co.uk/covid-19/nlrp3-inflammasome-a-novel-drug-target-for-treating-severely-ill-covid-19-patients/
- ʻO Dolinay T, Kim YS, et al 2012. ʻO nā cytokines inflammasome-regulated he mau mea hoʻolaha koʻikoʻi o ka hōʻeha ʻeha ʻeha. Am J Respir Crit Care Med, 185 (11) (2012), pp. 1225-1234. DOI: https://doi.org/10.1164/rccm.201201-0003OC
- Angeline XH Goh, Sebastien Bertin-Maghit, Siok Ping Yeo, Adrian Ho, Heidi Derks, Alessandra Mortellaro & Cheng-I Wang (2014) He kanaka hou anti-interleukin-1β neutralizing monoclonal antibody e hōʻike ana i ka pono vivo, mAbs, 6:3 , 764-772, DOI: https://doi.org/10.4161/mabs.28614
- Cohen, J. Designer antibodies hiki ke kaua i ka COVID-19 ma mua o ka hiki ʻana mai o nā kano. DOI: https://doi.org/10.1126/science.abe1740
- Ledford, H. 2020. He alahaka paha nā lāʻau lapaʻau antibody i kahi kano coronavirus — akā e pōmaikaʻi anei ka honua? ʻAno. Hoʻopuka ʻia ma ka lā 11th ʻAukake 2020. DOI: https://doi.org/10.1038/d41586-020-02360-y
- NIH.gov 2020. Hoʻomaka ʻo NIH i ka hoʻokolohua lapaʻau e hoʻāʻo i ka mālama antibody i nā maʻi maʻi COVID-19 i hoʻopaʻa ʻia. Paʻi ʻia ma ʻAukake 4, 2020. Loaʻa ma ka pūnaewele ma https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients
***
, Anakinra (monoclonal antibody) and Rilonacept (fusion protein) can be....){kind=link}